Drug
Nktr 214
Nktr 214: highest development phase Phase 1, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| NKTR-214 (Cohort A) NCT03835533 | Phase 1 | Metastatic Castration-resistant Prostate Cancer |
Latest
No recent events.
Follow Nktr 214 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.